MarketWatch #7
This week, we’re going to take a look at the 3 of the companies that have cut their teeth on new, groundbreaking tech to pave the way in delivering a vaccine during the horror movie-like experience that we have had for the last year and a half.
“I cant wait to finally be free” — Everyone in 2020
Disclaimer: MarketWatch is for entertainment purposes only. It is important that ALL investors conduct their own market research to determine the best investments for their portfolio. Please do not blindly follow me or any random person on the internet, there are professionals for that. MarketWatch is intended to give you insight into my investment portfolio and my analysis of each investment that is discussed. Please feel free to share any comments or questions below.
Covid-19, the coronavirus, the pandemic, the “Rona” — whatever you want to call it, it’s finally starting to get under control. No matter your sociopolitical views on the subject, I think we are all ready to move on from this depressing virus.
To remember the impact this virus had on our world, it’s easy — drive down to your local grocery store that’s now closed or look on your phone for which places offer new options for contactless delivery. There have been major drawbacks to this virus and also incredible solution-focused innovations that were created out of necessity.
This week, we’re going to take a look at the 3 of the companies that have cut their teeth on new, groundbreaking tech to pave the way in delivering a vaccine during the horror movie-like experience that we have had for the last year and a half.
No time to waste, we need the cure!
The Race to a Vaccine
Moderna (MRNA): The Company of Major Gains! This time last year, Moderna was a $20 stock, today, you can’t get it for less than $130. And the only reason you can get it that cheap is because they just had their regularly scheduled pull back. History: In May 2020 Moderna saw a dip similar to the one happening now, this happened after they saw significant growth — a similar trend in several of your favorite stocks. In July, there was another pullback after growth. Another in December, and now they’re going through one in March.
Historical charts can help with predicting market movement in the future. This method of forecasting stocks is not a one-size-fits-all, but it does give you an idea of a stock’s volatility performance in similar climates and quarters.
Pfizer (PFE): The Dark Horse of the Pandemic. Pfizer is the most affordable stock of the three vaccine achievers and this is the one that I believe could have the most upside. Of the 3, Pfizer has had the least stock inflation, a high vaccine effective rate, and the highest dividend payout percentage of the three. This is worth noting because a dividend is the investor paycheck a company sends you after they’ve made more money than they needed. Pfizer has a long-standing history of paying out this check, and that represents strong financials and a commitment to shareholders.
So to recap: Their price is low, they pay you for investing, and they are making a vaccine that works!
I’d suggest you add this stock to your watchlist to see how the next few months go, earnings come out 4/27 and we could see this company make a comfortable shift in a positive direction.
Johnson & Johnson (JNJ): The one-hit-wonder, Johnson and Johnson was able to create a single-shot vaccine to battle the virus. Though the effectiveness numbers are lower than the other 2 vaccine companies, it is nice to see a familiar face helping to lead the charge in the race for a cure. With that said, I expected to see a more dramatic shift in JNJ stock this year.
As I have said before and I will say it again, staying ahead of the curb and making investment decisions based on logic will prove to be a much better and comfortable way to invest than following market trends. Do your research and trust what you put your hard-earned money into, this way you can sleep better at night knowing that you have placed your money in the right places.